CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 70 enrolled
Drug / intervention
NST 6179 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05181085
NCT05181085Phase 1Completed
CompareCT.gov

A Phase 1, First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST 6179 in Healthy Subjects

NorthSea Therapeutics B.V.·interventional·Posted Jan 6, 2022·Updated Jun 24, 2024

In Brief

A Phase 1 clinical trial evaluating NST 6179 and Placebo for Short Bowel Syndrome and Parenteral Nutrition Associated Liver Disease. Completed, enrolled 70 participants across 1 site.

Detailed Summary

A double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of NST-6179 in healthy male and female subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShort Bowel Syndrome, Parenteral Nutrition Associated Liver Disease
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedJan 6, 2022
Enrollment StartNov 11, 2021
Primary CompletionMay 27, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.5 years ago

Interventions

NST 6179drug

orally administered, fully synthetic medium chain fatty acid (MCFA) analogue

Placebodrug

inactive analogue